指南与共识湿疹皮炎与荨麻疹

在临床实践中测量特应性湿疹控制与瘙痒强度:HOME-CP倡议的共识声明

Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
指南 / 共识 · JAMA Dermatol · 2022-01-01

HOME临床实践倡议通过系统综述和共识会议,推荐RECAP和ADCT用于测量特应性湿疹控制,推荐3种瘙痒强度测量工具(峰值24小时NRS-itch及PROMIS瘙痒问卷的1周平均和峰值NRS-itch),鼓励临床医生和患者将这些验证充分、快速易用的工具纳入临床,以辅助而非替代医患交流。

要点

  • 推荐RECAP和ADCT用于临床测量特应性湿疹控制,投票反对比例分别为5%和10%。
  • 推荐峰值24小时NRS-itch及PROMIS瘙痒问卷的1周平均和峰值NRS-itch测量瘙痒强度。
  • 这些评估旨在增强而非替代医患交流,并支持真实世界研究和医疗改进。

核心结论

  • 鼓励临床医生和患者将验证充分、快速易用且易于使用的工具纳入临床,选择最适合其需求的工具。
  • 这些评估旨在增强而非替代医患交流,并支持真实世界研究和医疗改进。

研究设计与样本

  • HOME临床实践倡议通过系统综述识别测量湿疹控制和瘙痒强度的可用工具,并在HOME VIII虚拟在线会议(2020年10月6日和10月9日)进行共识流程。
  • 共识定义为反对投票者少于30%。

主要发现

  • 共识别7种测量湿疹控制的工具,其中RECAP和ADCT被推荐(反对投票分别为63票中3票[5%]和69票中7票[10%])。
  • 单一问题患者整体评估获得支持,但当前可用工具未达成共识。
  • 共识别6种瘙痒强度工具,其中3种被推荐:峰值24小时NRS-itch,以及PROMIS瘙痒问卷的1周平均和峰值NRS-itch(反对投票分别为63票中11票[17%]、63票中14票[22%]和59票中16票[27%])。

关键数值与推荐

  • RECAP:反对投票63票中3票(5%)。
  • ADCT:反对投票69票中7票(10%)。
  • 峰值24小时NRS-itch:反对投票63票中11票(17%)。
  • PROMIS瘙痒问卷1周平均NRS-itch:反对投票63票中14票(22%)。
  • PROMIS瘙痒问卷1周峰值NRS-itch:反对投票59票中16票(27%)。

临床怎么用

  • 临床医生和患者被鼓励将这些验证充分、快速易用且易于使用的工具纳入临床,选择最适合其需求的工具。
  • 这些评估旨在增强而非替代医患交流,并支持真实世界研究和医疗改进。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list of validated, feasible instruments to measure atopic eczema in clinical care. Prior work identified symptoms and long-term control as the most important domains to measure in clinical practice. The Patient-Oriented Eczema Measure (POEM) and the Patient-Oriented Scoring Atopic Dermatitis Index (PO-SCORAD) were recommended by consensus to measure symptoms in clinical practice, but a need for instruments to measure itch intensity specifically was recognized. The HOME group also previously decided that long-term control should be captured by repeated measurements of eczema control. Recommended instruments to measure eczema control in clinical practice have not been defined. OBJECTIVE: To recommend instruments to measure eczema control and itch intensity in patients with atopic eczema in clinical practice. EVIDENCE REVIEW: Available instruments to measure eczema control and itch intensity were identified through systematic reviews, informing a consensus process held at the HOME VIII virtual online meeting (October 6 and October 9, 2020). Feasibility aspects were highlighted to optimize instrument selection for the clinical practice. Consensus on an instrument was reached if fewer than 30% of the voters disagreed. FINDINGS: Of 7 identified instruments, the Recap of Atopic Eczema (RECAP) and Atopic Dermatitis Control Tool (ADCT) were the recommended instruments to measure eczema control (3 of 63 [5%] and 7 of 69 [10%] of voters disagreed, respectively). A single-question patient global assessment garnered support, but the current available instrument did not reach consensus. Six available itch-intensity instruments were identified. Of them, 3 instruments were recommended by consensus: a peak 24-hour numeric rating scale (NRS)-itch, and 1-week NRS-itch instruments from the Patient-Reported Outcomes Measurement Information System (PROMIS) Itch Questionnaire, measuring average and peak itch (11 of 63 [17%], 14 of 63 [22%], and 16 of 59 [27%] voters disagreed, respectively). CONCLUSIONS AND RELEVANCE: Clinicians and patients are encouraged to incorporate these well-validated, quick-to-perform, and easy-to-use instruments into their clinic, selecting the instruments that best fit their need. These assessments are meant to enhance, not replace, the patient-clinician encounter, and to support real-world research and health care improvement.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative. JAMA Dermatol. 2022. PMID: 36223090. doi:10.1001/jamadermatol.2022.4211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。